• settings
  • CC
  • 360p
  • 480p
  • 720p
  • 1080p
2,004 VIEWS | 0 LIKES

Tecan AACC 2015 Symposium Dr. K.Y. Chun

from Tecan Group Ltd.

Dr Kelly Chun explains what is biotherapeutics drugs and what immunogenicity risks are related to treatments with such drugs. Furthermore, she describes that auto antibodies can on the other end reduce the efficacy of biotherapeutics. Altogether, Dc Chun illustrates the relevance of measuring immunogenecity of biotherapeutics drugs in patients and the benefits of proper monitoring of drug immunogenecity in the adjustment of the treatment. Dc Chun emphasizes in her presentation the challenges to develop adequat Anti-Drug Assay (ADA) and the need to properly train the physicians on the interpretation of those ADA. Dr Chun takes in particular the example of ADA developped for Inflammatroy Bowel Disease (IBD) drugs.

about 5 years ago

Recommended Videos
Latest Videos

We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy